NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental ...
The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo. NanoViricides said its proposal for the Phase II trial has already been approved …